

1 **Differences in coagulation responses to vascular injury between uninterrupted**

2 **dabigatran and apixaban - a clinical prospective randomized study**

3

4 Yasuhiro Ikami, M.D.,^a Daisuke Izumi, M.D.,^a Shinya Fujiki, M.D.,^a Hirotaka Sugiura,

5 M.D.,^b Sou Otsuki, M.D.,^a Naomasa Suzuki, M.D.,^a Yuta Sakaguchi, M.D.,^a Takahiro

6 Hakamata, M.D.,^a Yuki Hasegawa, M.D.,^a Nobue Yagihara, M.D.,^a Kenichi Iijima, M.D.,^a

7 Takahiro Tanaka, Ph.D.,^c Masahiro Ishizawa, M.D.,^c Masaomi Chinushi, M.D.,^d Tohru

8 Minamino, M.D.,^{a,e} and Takayuki Inomata, M.D.^a

9

10 ^aDepartment of Cardiovascular Medicine, Niigata University Graduate School of Medical
11 and Dental Sciences, Niigata, 951-8510, Japan

12 ^bDepartment of Cardiovascular Medicine, Niigata Medical Center, Niigata, 950-2022, Japan

13 ^cClinical and Translational Research Center, Niigata University Medical and Dental Hospital,
14 Niigata, 951-8520, Japan

15 ^dSchool of Health Science, Faculty of Medicine, Niigata University, Niigata, 951-8518,
16 Japan

17 ^eDepartment of Cardiovascular Biology and Medicine, Juntendo University Graduate School
18 of Medicine, Tokyo, 113-8421, Japan

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 **Short title:** Differences in coagulation responses among DOACs

21 **Total word count:** 4927 words

22

23 **Address correspondence to:**

24 Daisuke Izumi M.D., Ph.D.

25 E-mail: dizumi@med.niigata-u.ac.jp

26 Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and

27 Dental Sciences

28 1-757 Asahimachidori, Chuo-ku, Niigata 951-8510, Japan

29 Phone: +81-25-227-2185, Fax: +81-25-227-0774

30 **Abstract**

31

32 **Background:** The coagulation response during vascular injury with uninterrupted
33 administration of direct oral anticoagulants (DOACs) has not been elucidated. Our aim was to
34 evaluate differences in coagulation responses after vascular injury between uninterrupted
35 direct thrombin inhibitor and direct factor Xa inhibitor recipients.

36

37 **Methods:** Patients scheduled for catheter ablation for atrial fibrillation were randomly
38 assigned to receive dabigatran or apixaban in this prospective, randomized, comparative,
39 parallel-group study. Venous blood was collected three times: 180 minutes after taking the
40 anticoagulant on the day before the procedure, before vascular punctures of the ablation
41 procedure, and 10–15 minutes after the start of vascular punctures.

42

43 **Results:** Forty-two patients were enrolled. The prothrombin fragment 1+2 (F1+2) level, the
44 primary endpoint, was much larger after vascular puncture in the uninterrupted dabigatran
45 recipients (median: 83 pmol/L; interquartile range: 56–133 pmol/L) than in the uninterrupted
46 apixaban recipients (median: 1 pmol/L; interquartile range: –3–19 pmol/L; $P < 0.001$).
47 Antithrombin levels decreased after vascular puncture in dabigatran recipients, and both
48 protein C and antithrombin levels decreased after vascular puncture in apixaban recipients.

49

50 **Conclusions:** Unlike uninterrupted apixaban, uninterrupted dabigatran does not inhibit

51 thrombin generation in response to vascular injury.

52

53 **Non-standard Abbreviations and Acronyms**

54 AF Atrial fibrillation

55 DOAC Direct oral anticoagulant

56 F1+2 Prothrombin fragment 1+2

57 IQR Interquartile range

58 SFMC Soluble fibrin monomer complex

59

60 **Clinical perspective**

61 **What is new?**

62 ● To the best of our knowledge, this is the first randomized clinical comparison of the
63 effects of direct thrombin and factor Xa inhibitors on the physiological coagulation and
64 anticoagulation system after vascular injury while direct oral anticoagulants (DOACs)
65 serum levels were at the peak phase.

66 ● Unlike uninterrupted apixaban, uninterrupted dabigatran does not inhibit thrombin
67 generation in response to vascular injury.

68 ● This study shows that physiological anticoagulation factors are consumed during
69 vascular injury in patients receiving DOACs.

70

71 **What are the clinical implications?**

72 ● The difference in the thrombin generation response during vascular injury between
73 uninterrupted dabigatran and apixaban may be one of the reasons for different clinical
74 outcomes of thrombotic and hemorrhagic complications.

75 ● DOACs may inhibit an excessive coagulation response by retaining physiological
76 anticoagulation factors.

77

78 **Introduction**

79 Atrial fibrillation (AF) has major clinical implications for patients' quality of life,
80 morbidity with ischemic stroke and heart failure, and mortality (**1–6**). Anticoagulation
81 therapy is recommended for patients with risk factors for thromboembolism or during the
82 perioperative period of catheter ablation for AF (**7,8**). Direct oral anticoagulants (DOACs),
83 which carry a lower risk of bleeding and interact less with diet than other anticoagulants, are
84 commonly used for anticoagulation therapy (**9–11**). Uninterrupted administration of DOACs
85 is becoming more common during the perioperative period of catheter ablation for AF
86 because recent randomized clinical studies of such treatment showed that the risk of major
87 bleeding was lower than or similar to that with uninterrupted warfarin treatment (**12–15**). In
88 addition, in these randomized controlled trials, in which DOACs and warfarin were
89 administered during the perioperative period of AF ablation, the frequency of hemorrhagic
90 complications among patients who received dabigatran was conspicuously low (**13**). However,
91 the reason for the low risk of major bleeding complications when catheter ablation is
92 performed during the peak phase of dabigatran is unclear (**13**). Therefore, this multicenter,
93 randomized study evaluated differences in coagulation responses, including thrombin
94 production after vascular injury, between direct thrombin inhibitor and direct factor Xa
95 inhibitor recipients.

96

97 **Methods**

98 **Study Design**

99 This prospective, open-label, randomized, comparative, parallel-group study was
100 conducted at two centers, Niigata University Medical and Dental Hospital and Niigata
101 Medical Center, from August 2019 to March 2021. It was performed in accordance with the
102 guiding principles of the Declaration of Helsinki and in compliance with the Clinical Trial
103 Act, a Japanese law designed to ensure that researchers monitor and adhere to the study
104 criteria. The Niigata University Clinical Research Central Review Board approved the study
105 protocol (number SP18014), which was included in the Japan Registry for Clinical Trials (ID
106 jRCT1031190030). Informed consent was obtained from all patients in accordance with these
107 regulations. The institutional review board comprehensively conducted an ethical review of
108 all participating facilities.

109
110 **Participants**

111 Eligible patients were 40–80 years of age, scheduled for catheter ablation for
112 paroxysmal or persistent AF according to the JCS/JHRS 2019 Guideline on
113 Non-Pharmacotherapy of Cardiac Arrhythmias (7), were eligible for treatment with
114 dabigatran (a direct thrombin inhibitor) or apixaban (a direct factor Xa inhibitor) according to
115 the prescribing guidelines in Japan (9), and provided informed consent to participate. The

116 main exclusion criteria were (1) a history of intracranial hemorrhage or bleeding in other
117 important organs; (2) the presence of mechanical heart valves or hemodynamically significant
118 mitral valve stenosis; (3) moderately severe or worse hepatic dysfunction (Child-Pugh class B
119 or C); (4) renal dysfunction characterized by a Cockcroft–Gault estimated creatinine clearance
120 <50 mL/min; (5) conditions with a high risk of bleeding (e.g., uncontrolled severe
121 hypertension, active malignant tumors, congenital or acquired bleeding disorders, active
122 ulcerative gastrointestinal disorders, treatment with two or more antiplatelet agents); and (6) a
123 New York Heart Association class III or worse heart failure, left ventricular ejection fraction
124 of 35% or less according to echocardiography, or a history of hospitalization for heart failure
125 within 1 year before the study.

126

127 **Interventions**

128 *Patient assignment*

129 Participants were randomly assigned in a 1:1 ratio to receive dabigatran or apixaban,
130 and the random allocation sequence was computer generated by a research physician.
131 Dynamic allocation with a minimization method was used to assign patients. The adjusting
132 factors were age, gender, and CHADS₂ score (calculated as 1 point each for a history of
133 hypertension, diabetes, recent heart failure, and age ≥ 75 years and 2 points for a history of a
134 stroke or transient ischemic attack) (16). A comprehensive medical history review, physical

135 examination, blood tests, and transthoracic echocardiography were performed after obtaining
136 consent from the participants.

137

138 *The dose of the designated anticoagulants*

139 If an anticoagulant drug different from the designated drug had been used before the
140 study, it was discontinued before drug assignment. After the drug assignment, we
141 administered the designated DOACs, and administration continued until after catheter
142 ablation for AF. Dabigatran was administered at a dose of 150 mg twice daily or, if dosage
143 adjustment was required (e.g., for patients aged ≥ 75 years, those taking P-glycoprotein
144 inhibitors, or those with a history of gastrointestinal bleeding), 110 mg twice daily. Apixaban
145 was administered at a dose of 5 mg twice daily or, if dose adjustment was required (≥ 2 of the
146 following criteria: age of ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥ 1.5 mg/dL),
147 2.5 mg twice daily. The designated DOACs were administered at least 1 week before catheter
148 ablation for AF.

149

150 *Examinations during hospitalization, including blood sampling before and after vascular*
151 *puncture*

152 Participants were admitted to the hospital two days before the ablation procedure.
153 Baseline measurements, physical examinations, blood tests, electrocardiography, and

154 transthoracic echocardiography were performed at admission. Venous blood was collected
155 three times to investigate the effect of vascular injury on the coagulation system: on the day
156 before the procedure, 180 minutes after the DOAC was administered (i.e., when serum levels
157 of the DOAC are at the peak phase) (17); before vascular puncture for the ablation procedure;
158 and 10–15 minutes after the start of vascular puncture, which was performed via a venous
159 sheath introducer after all sheath introducers were inserted and before intravenous
160 administration of unfractionated heparin. We planned not to use data from patients who
161 required more than 15 minutes to insert the sheath introducers. The final DOAC dose was
162 administered 1-2 hours before the ablation procedure (Figure 1).

163 The vascular puncture was performed according to the modified Seldinger method.
164 Conventional anatomical landmarks, palpation, and real-time two-dimensional vascular
165 echocardiography were used to locate the internal jugular veins, femoral arteries, and femoral
166 veins (18,19). In all patients undergoing AF ablation, four or five vascular sheath introducers
167 were inserted: one or two 8 Fr (SL0; St. Jude Medical Japan Co. Ltd., Tokyo, Japan) and one
168 8.5 Fr (SR0; St. Jude Medical Japan Co. Ltd.) into the femoral vein; one 7.2 Fr (Medikit
169 Supersheath; Medikit Co. Ltd., Tokyo, Japan) into the internal jugular vein; and one 3 Fr
170 (XEMEX, Zeon Medical, Tokyo, Japan) into the femoral artery.

171 We evaluated the prothrombin fragment 1+2 (F1+2) levels as a marker of thrombin
172 generation, soluble fibrin monomer complex (SFMC) as a marker of coagulation activation,

173 and D-dimer as a marker of coagulation. Similarly, we evaluated protein C, protein S, and
174 antithrombin levels as physiological coagulation inhibitors. Sample measurements were made
175 at an external institution unrelated to this study. We used an ELISA (Enzygnost F1+2
176 [Monoclonal]; Siemens Healthcare Diagnostic Corporation, Tokyo, Japan) to determine the
177 F1+2 level, a hemagglutination assay (FM test; Fujirebio Inc., Tokyo, Japan) or latex
178 photometric immunoassay (Iatro SF II; LSI Medience Co., Tokyo, Japan) to quantify SFMC
179 level, and functional assays (HemosIL ProClot and HemosIL PS-clot, respectively, I.L. Japan
180 Co., Ltd., Tokyo, Japan) to quantify protein C and S levels. We used the chromogenic
181 substrate method (Testzym S ATIII, Sekisui Medical Co., Ltd., Tokyo, Japan) to measure
182 antithrombin activity and a latex agglutination assay to measure D-dimer levels (LATECLE
183 D-dimer, KAINOS Laboratories, Inc., Tokyo, Japan).

184

185 **Endpoints**

186 The primary endpoint of this study was the change in F1+2 levels before and after
187 vascular puncture for both DOACs. Secondary endpoints were F1+2, protein C, protein S,
188 and antithrombin levels and the changes in the latter three levels between vascular punctures
189 for both DOACs. The exploratory endpoints were all D-dimer levels and the changes in
190 D-dimer and SFMC levels between vascular punctures for both DOACs. All adverse events
191 during this study were recorded, analyzed, and classified as serious or nonserious. The events

192 were reported to the Data and Safety Monitoring Committee and evaluated for

193 recommendations to continue the study.

194

195 **Statistical Analysis**

196 Based on previous findings (20), we hypothesized that the increase in F1+2 levels
197 before and after vascular puncture would be approximately 2.5 times higher for dabigatran
198 than for apixaban. Because we used 80% power and 0.05 bilateral alpha levels, the study had
199 to include at least 36 patients to reach statistical significance. Given the potential number of
200 dropouts, we set the target number of participants at 40.

201 The safety analysis set included all enrolled patients. The full analysis set included
202 all enrolled patients except those with critical protocol violations (e.g., no consent or major
203 procedural violations). The per protocol set included all enrolled patients from the full
204 analysis set without major protocol deviations.

205 The study endpoints were analyzed for the full analysis set. Continuous variables
206 were calculated as means and standard deviations for normally distributed data and as
207 medians and interquartile ranges (IQRs) for nonnormally distributed data. Categorical
208 variables were calculated as numbers (percentages). Patient characteristics were compared
209 with chi-square tests (for five or more events) and Fisher's exact test (for fewer than five
210 events) for categorical variables, *t*-tests for normally distributed continuous variables, and the

211 Wilcoxon rank-sum test for continuous variables with a skewed distribution. All *P*-values
212 were two-sided, and values <0.05 were statistically significant. We used SPSS Statistics 27
213 (IBM Corporation, Armonk, NY, USA) to perform all statistical analyses.

214

215 **Results**

216 **Patient Characteristics**

217 Of the 42 patients randomly assigned to receive dabigatran or apixaban, 1 patient
218 assigned to receive dabigatran withdrew from the study before drug administration. The trial
219 was terminated because the target number of enrolled patients was reached. Persistent AF was
220 found in nine patients (45%) who received dabigatran and seven patients (33%) who received
221 apixaban. Thirty-seven patients (17 receiving dabigatran and 20 receiving apixaban)
222 completed the study. However, one patient receiving dabigatran was excluded from the per
223 protocol set because of a protocol violation (a mistake in the blood sampling procedure).
224 There were no changes to trial outcomes after the trial commenced. The demographic and
225 clinical characteristics of the participants of both groups were similar (Table 1).

226

227 **Vascular Punctures**

228 We found no significant difference between the two groups from the final DOAC
229 administration to the blood samplings (Table 2). In addition, the number of sheath introducers
230 inserted did not differ significantly between the two groups (Table 2).

231

232 **Attrition and Adverse Events**

233 During the study period, five patients (four receiving dabigatran and one receiving
234 apixaban) dropped out (Figure 2). Of those receiving dabigatran, 1 voluntarily withdrew
235 consent, 1 patient dropped out because of upper gastrointestinal symptoms, and 2 suffered
236 unexpected adverse events during ablation procedure (sedative-induced coronary spasm in 1,
237 delay of 15 minutes or more in vascular puncture in the other). Of those receiving apixaban, 1
238 patient withdrew because the catheter ablation procedure was canceled. Of those receiving
239 dabigatran, 2 suffered adverse events that may have been caused by the study (upper
240 gastrointestinal tract symptoms in 1 and gastric ulcer associated with discontinuation of
241 proton pump inhibitor therapy in 1). Thus, the per protocol set included 36 patients.

242

243 **Primary Endpoint**

244 The change in F1+2 levels after vascular punctures was much larger in participants
245 taking dabigatran (median: 83 pmol/L [IQR: 56 to 133 pmol/L]) than in those taking
246 apixaban (median: 1 pmol/L [IQR: -3 to 19 pmol/L] pmol/L); $P < 0.001$; Figure 3).

247

248 **Secondary Endpoints**

249 F1+2 levels before vascular puncture were slightly higher in the dabigatran
250 recipients (median: 113 pmol/L [IQR: 93 – 141 pmol/L]) than in the apixaban recipients
251 (median: 84 pmol/L [IQR: 72 – 96 pmol/L]; $P < 0.001$). Unlike the apixaban recipients,
252 dabigatran recipients showed a significant increase in F1+2 levels after vascular puncture
253 (Figure 3). Antithrombin levels were significantly higher in the apixaban recipients before
254 and after vascular puncture. Moreover, protein C and S levels were significantly higher in the
255 dabigatran recipients before and after puncture (Figure 4). In both groups, F1+2 levels before
256 vascular puncture were slightly lower than 3 hours after the administration of DOACs on the
257 day before the procedure, when serum DOAC levels are in peak phase; in dabigatran
258 recipients, median levels were 113 pmol/L (IQR: 93 to 141 pmol/L) vs. 136 pmol/L (IQR:
259 112 to 151 pmol/L), respectively ($P = 0.039$); in apixaban recipients, median levels were 84
260 pmol/L (IQR: 72 to 96 pmol/L) vs. 109 pmol/L (IQR: 88 – 128 pmol/L), respectively ($P <$
261 0.001) (Figure 3). In the dabigatran recipients, antithrombin levels decreased after vascular
262 puncture, whereas in apixaban recipients, protein C and antithrombin levels decreased after
263 vascular puncture (Figure 4).

264

265 **Exploratory Endpoints**

266 We found no significant difference in pre-puncture D-dimer levels between the
267 dabigatran (median: 0.17 $\mu\text{g/mL}$ [IQR: 0.05 to 0.23 $\mu\text{g/mL}$]) and apixaban recipients
268 (median: 0.21 $\mu\text{g/mL}$ [IQR: 0.14 to 0.30 $\mu\text{g/mL}$]; $P = 0.067$) or in post-puncture D-dimer
269 levels between the dabigatran (median: 0.12 $\mu\text{g/mL}$ [IQR: 0.05 to 0.23 $\mu\text{g/mL}$]) and the
270 apixaban recipients (median: 0.15 $\mu\text{g/mL}$ [IQR: 0.05 to 0.25 $\mu\text{g/mL}$]; $P = 0.42$). We also
271 found no significant difference in the change in D-dimer levels between the dabigatran
272 (median: -0.01 $\mu\text{g/mL}$ [IQR: -0.08 to 0 $\mu\text{g/mL}$]) and the apixaban recipients (median:
273 -0.04 $\mu\text{g/mL}$ [IQR: -0.08 to 0.02 $\mu\text{g/mL}$]; $P = 0.92$; Figure 4). Meanwhile, the SFMC
274 changed positively ($P = 0.58$) after vascular puncture in two dabigatran recipients and one
275 apixaban recipient. SFMC was measured with two different methods, but the difference in the
276 method did not affect the change in SFMC ($P > 0.999$).

277

278 **Discussion**

279 Our major findings were that (1) after vascular puncture, F1+2 levels increased more
280 in the uninterrupted dabigatran recipients than in the uninterrupted apixaban recipients, and
281 (2) Some coagulation inhibitors, such as antithrombin and protein C, appeared to be
282 consumed after vessel puncture.

283 To our knowledge, this is the first randomized clinical comparison of the effects of
284 direct thrombin and factor Xa inhibitors on the physiological coagulation and anticoagulation

285 system after vascular injury while serum levels of DOAC were at the peak phase. Several
286 previous studies of the anticoagulant effect of DOACs have shown that thrombin generation
287 or levels of coagulation activation markers, such as F1+2 and soluble fibrin, are suppressed to
288 some extent not only during the peak phase but also during the trough phase of DOACs (20–
289 23). The degree of suppression of F1+2 levels at the peak levels of DOAC in our study was
290 similar to those previously reported (20–23). According to our previous report, thrombin
291 production was increased at dabigatran and apixaban trough levels during vascular injury, but
292 the response at DOAC peak levels was unknown (20). In this study, we found that the large
293 thrombin production after vascular puncture during the peak phase of dabigatran was similar
294 to the trough phase previously reported (20). Meanwhile, we found that an increased response
295 to thrombin generation after vascular puncture was not observed during the peak phase of
296 apixaban (20).

297 Unlike direct Xa inhibitors, direct thrombin inhibitors in the therapeutic range may
298 be less effective in suppressing initial thrombin generation associated with vascular injury
299 (24). Moreover, direct factor Xa inhibitors in the therapeutic range may suppress thrombin
300 bursts after the initial thrombin generation (25). This finding may be the reason for the
301 difference in thrombin-producing ability after vascular injury observed in this study.
302 Compared with apixaban, dabigatran appeared to inhibit hemorrhagic complications such as
303 intracranial hemorrhage and bleeding complications during catheter procedures (12–15,26).

304 In contrast, the risk of thrombotic events such as asymptomatic cerebral infarction during
305 ablation may be greater in patients taking dabigatran (**15,23,27**). The difference in the
306 thrombin generation response between both drugs observed in our study may be one of the
307 reasons for the different clinical outcomes of thrombotic and hemorrhagic complications
308 mentioned above.

309 Our results suggest that dabigatran increased the protein C and S levels, whereas
310 apixaban increased antithrombin levels. DOACs may prolong clotting time, and protein C,
311 protein S, and antithrombin activity may be overestimated (**28,29**). Meanwhile, antithrombin
312 or protein C levels decreased after vascular puncture in both groups in this study. Although
313 there is an interaction of DOACs on the measured values, before-and-after comparisons are
314 possible. Therefore, decreased physiological anticoagulant factors during vascular puncture
315 may indicate negative feedback for a hypercoagulable state in the DOAC recipients.

316 Our study had some limitations. The sample size was relatively small, and the study
317 was underpowered to determine the difference in the increasing reaction of the SFMC. Blood
318 samples obtained before vascular puncture might not accurately reflect the peak levels of
319 DOACs because the elapsed time from the last administration of DOACs was approximately
320 70–80 minutes (**30,31**). However, F1+2 levels 3 hours after the administration of DOACs at
321 admission, when DOAC levels peaked, were equivalent to or higher than F1+2 levels before

322 vascular puncture. Therefore, the comparison of each measurement before and after vascular
323 puncture in this study is considered an evaluation, while DOAC levels are fairly high.

324

325 **Conclusions**

326 In contrast to uninterrupted apixaban, uninterrupted dabigatran did not inhibit
327 thrombin generation in response to vascular injury.

328

329 **Sources of Funding**

330 This study was supported by the Clinical Research Support Program from Niigata
331 University Medical and Dental Hospital.

332

333 **Disclosures**

334 None

335

336

337 **References**

- 338 1. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a
339 systematic review. *Am J Med.* 2006; 119:448.e1-e19.
- 340 2. Kimura K, Minematsu K, Yamaguchi T, Japan Multicenter Stroke Investigators'
341 Collaboration (J-MUSIC). Atrial fibrillation as a predictive factor for severe stroke and early
342 death in 15,831 patients with acute ischaemic stroke. *J Neurol Neurosurg Psychiatry.* 2005;
343 76:679-683.
- 344 3. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A
345 meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. *Eur J*
346 *Heart Fail.* 2009; 11:676-683.
- 347 4. Cheng M, Lu X, Huang J, Zhang J, Zhang S, Gu D. The prognostic significance of atrial
348 fibrillation in heart failure with a preserved and reduced left ventricular function: insights
349 from a meta-analysis. *Eur J Heart Fail.* 2014;16:1317-1322.
- 350 5. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M,
351 Yusuf S, Pfeffer MA; CHARM Investigators. Atrial fibrillation and risk of clinical events in
352 chronic heart failure with and without left ventricular systolic dysfunction: results from the
353 Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM)
354 program. *J Am Coll Cardiol.* 2006; 47:1997-2004.

- 355 6. Rivero-Ayerza M, Scholte op Reimer W, Lenzen M, Theuns DA, Jordaens L, Komajda M,
356 Follath F, Swedberg K, Cleland JG. New-onset atrial fibrillation is an independent predictor
357 of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure
358 Survey. *Eur Heart J*. 2008; 29:1618-1624.
- 359 7. Nogami A, Kurita T, Abe H, Ando K, Ishikawa T, Imai K, Usui A, Okishige K, Kusano K,
360 Kumagai K, et al. JCS/JHRS 2019 Guideline on non-pharmacotherapy of cardiac arrhythmias.
361 *Circ J*. 2021; 85:1104-1244.
- 362 8. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, Akar JG, Badhwar V,
363 Brugada J, Camm J, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus
364 statement on catheter and surgical ablation of atrial fibrillation. *Europace*. 2018; 20:e1-e160.
- 365 9. Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, Kusano K, Kobayashi Y,
366 Koretsune Y, Sasano T, et al. JCS/JHRS 2020 Guideline on pharmacotherapy of cardiac
367 arrhythmias. *Circ J*. 2022; 86:1790-1924.
- 368 10. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC
369 Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
370 *Eur Heart J*. 2016; 37:2893-2962.
- 371 11. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG,
372 Oldgren J, Reinecke H, Roldan-Schilling V, et al. The 2018 European Heart Rhythm

- 373 Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in
374 patients with atrial fibrillation. *Eur Heart J.* 2018; 39:1330-1393.
- 375 12. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS,
376 Hess S, Wells DS, Juang G, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K
377 antagonists for catheter ablation in non-valvular atrial fibrillation. *Eur Heart J.*
378 2015;36:1805-1811.
- 379 13. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K,
380 Serota H, Nordaby M, Guiver K, et al. Uninterrupted dabigatran versus warfarin for ablation
381 in atrial fibrillation. *N Engl J Med.* 2017; 376:1627-1636.
- 382 14. Kirchhof P, Haessler KG, Blank B, De Bono J, Callans D, Elvan A, Fetsch T, Van Gelder
383 IC, Gentlesk P, Grimaldi M, et al. Apixaban in patients at risk of stroke undergoing atrial
384 fibrillation ablation. *Eur Heart J.* 2018; 39:2942-2955.
- 385 15. Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbüchel H, Mont L, Morillo CA,
386 Abozguia K, Grimaldi M, Rauer H, et al. Uninterrupted edoxaban vs. vitamin K antagonists
387 for ablation of atrial fibrillation: the ELIMINATE-AF trial. *Eur Heart J.* 2019;40:3013-3021.
- 388 16. Gage BF, Waterman AD, Shannon W, Boehler M, Rich MW, Radford MJ. Validation of
389 clinical classification schemes for predicting stroke: results from the National Registry of
390 Atrial Fibrillation. *JAMA.* 2001; 285:2864-2870.

- 391 17. De Caterina R, Husted S, Wallentin L, De Caterina R, Husted S, Wallentin L, Andreotti F,
392 Arnesen H, Bachmann F, Baigent C. New oral anticoagulants in atrial fibrillation and acute
393 coronary syndromes: ESC Working Group on Thrombosis—Task Force on Anticoagulants in
394 Heart Disease position paper. *J Am Coll Cardiol*. 2012; 59:1413-1425.
- 395 18. Prabhu MV, Juneja D, Gopal PB, Sathyanarayanan M, Subhramanyam S, Gandhe S..
396 Ultrasound-guided femoral dialysis access placement: a single-center randomized trial. *Clin J*
397 *Am Soc Nephrol*. 2010; 5:235-239.
- 398 19. Troianos CA, Hartman GS, Glas KE, Skubas NJ, Eberhardt RT, Walker JD, Reeves ST.
399 Guidelines for performing ultrasound guided vascular cannulation: recommendations of the
400 American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists.
401 *J Am Soc Echocardiogr*. 2011; 24:1291-1318.
- 402 20. Otuki S, Izumi D, Suda M, Sato A, Hasegawa Y, Yagihara N, Iijima K, Chinushi M, Fuse
403 I, Minamino T. Effects of direct oral anticoagulants at the peak phase, trough phase, and after
404 vascular injury. *J Am Coll Cardiol*. 2018; 71:102-104.
- 405 21. Nakano Y, Kondo T, Osanai H, Murase Y, Nakashima Y, Asano H, Ajioka M, Sakai K,
406 Inden Y, Murohara T. Clinical usefulness of measuring prothrombin time and soluble fibrin
407 levels in Japanese patients with atrial fibrillation receiving rivaroxaban. *J Cardiol*. 2015;
408 65:185-190.

- 409 22. Tajiri K, Sato A, Harunari T, Shimojo N, Yamaguchi I, Aonuma K. Impact of rivaroxaban
410 compared with warfarin on the coagulation status in Japanese patients with non-valvular
411 atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels. *J Cardiol.*
412 2015; 65:191-196.
- 413 23. Nagao T, Higo S, Suzuki H, Teshima Y, Matsunaga S, Harada K, Shinoda N, Harada K,
414 Kato M, Marui N, et al. Prospective comparison of periprocedural coagulation markers
415 among uninterrupted anticoagulants for atrial fibrillation ablation. *Heart Rhythm.* 2020;
416 17:391-397.
- 417 24. Samama MM, Le Flem L, Guinet C, Gerotziafas G, Depasse F. Three different patterns of
418 calibrated automated thrombogram obtained with six different anticoagulants. *J Thromb*
419 *Haemost.* 2007; 5:2554-2556.
- 420 25. Shibeko AM, Lobanova ES, Panteleev MA, Ataullakhanov FI. Blood flow controls
421 coagulation onset via the positive feedback of factor VII activation by factor Xa. *BMC Syst*
422 *Biol.* 2010; 4:5.
- 423 26. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly
424 PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation.
425 *N Engl J Med.* 2009;361:1139-1151.
- 426 27. Nakamura K, Naito S, Sasaki T, Minami K, Take Y, Goto E, Shimizu S, Yamaguchi Y,
427 Suzuki N, Yano T, et al. Silent cerebral ischemic lesions after catheter ablation of atrial

- 428 fibrillation in patients on 5 types of periprocedural oral anticoagulation-predictors of
429 diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging. *Circ*
430 *J.* 2016; 80:870-877.
- 431 28. Mani H. Interpretation of coagulation test results under direct oral anticoagulants. *Int J*
432 *Lab Hematol.* 2014; 36:261-268.
- 433 29. Moser KA, Smock KJ. Direct oral anticoagulant (DOAC) interference in hemostasis
434 assays. *Hematology Am Soc Hematol Educ Program.* 2021; 2021:129-133.
- 435 30. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin
436 inhibitor dabigatran etexilate. *Clin Pharmacokinet.* 2008; 47:285-295.
- 437 31. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC,
438 Mosqueda - Garcia R. Safety, pharmacokinetics and pharmacodynamics of multiple oral
439 doses of apixaban, a factor Xa inhibitor, in healthy subjects. *Br J Clin Pharmacol.*
440 2013;76:776-786.

Table.1

Baseline characteristics

	Dabigatran group (n=20)	Apixaban group (n=21)	P value
Female, n (%)	4 (20)	4 (19)	1
Age, years	61.3 ± 8.5	63.8 ± 7.8	0.34
Type of atrial fibrillation, n (%)			0.44
Paroxysmal	11 (55)	14 (67)	
Persistent	9 (45)	7 (33)	
Chronic heart failure, n (%)	0	0	1
Hypertension, n (%)	11 (55)	14 (67)	0.44
Diabetes, n (%)	2 (10)	3 (14)	1
History of stroke or transit ischemic attack, n (%)	2 (10)	1 (5)	0.61
CHADS2 score	0.85 ± 0.81	0.95 ± 0.67	0.66
Low-dose anticoagulants, n (%)	2 (10)	0	0.23
Body weight, kg	72.0 ± 13.4	73.4 ± 13.1	0.74
Systolic blood pressure, mmHg	126 ± 16	123 ± 14	0.57
Diastolic blood pressure, mmHg	80 ± 12	77 ± 11	0.50
Heart rate, bpm	76 ± 12	71 ± 11	0.18
Body temperature, °C	36.2 ± 0.4	36.3 ± 0.6	0.53

Left ventricular ejection fraction, %	63.7 ± 6.7	63.2 ± 6.7	0.80
Aspartate aminotransferase, U/L	24 ± 7	28 ± 9	0.14
Alanine aminotransferase, U/L	25 ± 9	31 ± 13	0.10
Lactate dehydrogenase, U/L	191 ± 23	194 ± 25	0.72
Creatinine, mg/dL	0.83 ± 0.13	0.83 ± 0.15	0.90
Estimated creatinine clearance, mL/min	94.1 ± 22.2	92.7 ± 22.1	0.85
Hemoglobin A1c, %	5.8 ± 0.4	5.8 ± 0.5	0.83
Hemoglobin, g/dL	14.7 ± 1.4	14.8 ± 1.2	0.81


Table.2


Vascular puncture situation

	Dabigatran group (n=20)	Apixaban group (n=21)	P value
Number of internal jugular venous sheaths	1	1	1
Number of femoral venous sheaths	2.2 ± 0.4	2.1 ± 0.3	0.35
Number of femoral arterial sheaths	1	1	1
Time from last dose to pre-puncture blood collection, min	71 ± 29	79 ± 22	0.37
Time from last dose to post-puncture blood collection, min	149 ± 14	153 ± 19	0.46
Time from beginning of puncture to post-puncture blood collection, min	10.4 ± 0.7	10.5 ± 1.2	0.80

The day before procedure			The day of ablation	
Dabigatran	AM ●	PM ●	●	AM Ablation
Apixaban	●	●	●	Ablation
Sampling				

Figure 1. Study protocol. Venous blood was collected thrice to investigate the effect of vascular injury on the coagulation system in uninterrupted DOAC recipients: 180 minutes after the anticoagulant was administered on the day before the procedure, before the vascular punctures of the ablation procedure, and 10–15 minutes after the initiation of the vascular punctures.








Figure 4. Antithrombin, protein S, protein C, and D-dimer levels before and after vascular punctures and the changes in these levels after vascular punctures. Circles represent measurements outside the 1.5 × interquartile range.